首页 > 最新文献

Annals of Surgical Treatment and Research最新文献

英文 中文
Lateral pelvic lymph node dissection based on nodal response to neoadjuvant chemoradiotherapy in mid/low rectal cancer: a retrospective comparative cohort study. 基于新辅助放化疗对中/低位直肠癌淋巴结反应的侧盆腔淋巴结清扫:一项回顾性比较队列研究。
IF 1.2 4区 医学 Q3 SURGERY Pub Date : 2025-06-01 Epub Date: 2025-06-02 DOI: 10.4174/astr.2025.108.6.333
Tae-Gyun Lee, Duck-Woo Kim, Hong-Min Ahn, Hye-Rim Shin, Mi Jeong Choi, Min Hyeong Jo, Heung-Kwon Oh, Sung-Bum Kang

Purpose: Total mesorectal excision (TME) without lateral pelvic lymph node (LPN) dissection (LPND) is feasible in patients with mid/low rectal cancer showing a reduction in LPN size to ≤5 mm following neoadjuvant chemoradiotherapy (nCRT). We aimed to evaluate the clinical outcomes of selective LPNDs based on these criteria.

Methods: Patients with mid/low rectal cancer and LPNs >5 mm before nCRT were included and classified based on nCRT response (post-nCRT LPN size ≤5 mm [responsive] vs. >5 mm [persistent]) and surgical procedure (TME alone vs. TME + LPND). In the responsive group, LPND was selectively performed only if morphologic predictors of LPN metastasis were present. Clinical outcomes were analyzed across subgroups.

Results: Of 122 patients, 82 were in the responsive group. Within this group, 61 underwent TME alone and 21 underwent TME + LPND. No locoregional recurrence was observed in either subgroup of the responsive group, with similar systemic metastasis rates (13.1% vs. 14.3%, P > 0.99). The TME alone subgroup showed significantly smaller post-nCRT LPN sizes (1.7 ± 2.1 mm vs. 3.9 ± 1.8 mm, P < 0.001) and lower ycN positivity rates (31.1% vs. 71.4%, P = 0.001).

Conclusion: Selective LPND based on post-nCRT LPN size ≤5 mm and the absence of morphologic predictors of metastasis may serve as a feasible option for managing mid/low rectal cancer with enlarged LPNs, thereby optimizing local control and reducing unnecessary surgeries.

目的:对于新辅助放化疗(nCRT)后盆腔外侧淋巴结(LPN)缩小至≤5mm的中/低位直肠癌患者,全肠系膜切除(TME)而不切除盆腔外侧淋巴结(LPN) (LPN) (lnd)是可行的。我们的目的是根据这些标准评估选择性lnnd的临床结果。方法:纳入nCRT前中低位直肠癌伴lppn >5 mm的患者,并根据nCRT反应(nCRT后LPN大小≤5 mm[反应性]vs >5 mm[持续性])和手术方式(TME单独vs TME + LPND)进行分类。在反应组中,只有当LPN转移的形态学预测因素存在时,才选择性地进行LPN手术。对各亚组的临床结果进行分析。结果:122例患者中82例为应答组。本组单独TME 61例,TME + lpd 21例。两组患者均未见局部复发,全身转移率相似(13.1% vs 14.3%, P < 0.99)。单纯TME亚组ncrt后LPN大小(1.7±2.1 mm vs. 3.9±1.8 mm, P < 0.001)和ycN阳性率(31.1% vs. 71.4%, P = 0.001)明显减小。结论:基于ncrt后LPN大小≤5mm和无转移形态学预测因素的选择性LPN可能是治疗LPN扩大的中/低位直肠癌的可行选择,从而优化局部控制并减少不必要的手术。
{"title":"Lateral pelvic lymph node dissection based on nodal response to neoadjuvant chemoradiotherapy in mid/low rectal cancer: a retrospective comparative cohort study.","authors":"Tae-Gyun Lee, Duck-Woo Kim, Hong-Min Ahn, Hye-Rim Shin, Mi Jeong Choi, Min Hyeong Jo, Heung-Kwon Oh, Sung-Bum Kang","doi":"10.4174/astr.2025.108.6.333","DOIUrl":"10.4174/astr.2025.108.6.333","url":null,"abstract":"<p><strong>Purpose: </strong>Total mesorectal excision (TME) without lateral pelvic lymph node (LPN) dissection (LPND) is feasible in patients with mid/low rectal cancer showing a reduction in LPN size to ≤5 mm following neoadjuvant chemoradiotherapy (nCRT). We aimed to evaluate the clinical outcomes of selective LPNDs based on these criteria.</p><p><strong>Methods: </strong>Patients with mid/low rectal cancer and LPNs >5 mm before nCRT were included and classified based on nCRT response (post-nCRT LPN size ≤5 mm [responsive] <i>vs.</i> >5 mm [persistent]) and surgical procedure (TME alone <i>vs.</i> TME + LPND). In the responsive group, LPND was selectively performed only if morphologic predictors of LPN metastasis were present. Clinical outcomes were analyzed across subgroups.</p><p><strong>Results: </strong>Of 122 patients, 82 were in the responsive group. Within this group, 61 underwent TME alone and 21 underwent TME + LPND. No locoregional recurrence was observed in either subgroup of the responsive group, with similar systemic metastasis rates (13.1% <i>vs.</i> 14.3%, P > 0.99). The TME alone subgroup showed significantly smaller post-nCRT LPN sizes (1.7 ± 2.1 mm <i>vs.</i> 3.9 ± 1.8 mm, P < 0.001) and lower ycN positivity rates (31.1% <i>vs.</i> 71.4%, P = 0.001).</p><p><strong>Conclusion: </strong>Selective LPND based on post-nCRT LPN size ≤5 mm and the absence of morphologic predictors of metastasis may serve as a feasible option for managing mid/low rectal cancer with enlarged LPNs, thereby optimizing local control and reducing unnecessary surgeries.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"108 6","pages":"333-344"},"PeriodicalIF":1.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of pancreas transplantation over two decades: a single-center retrospective cohort study. 二十年来胰腺移植的结果:一项单中心回顾性队列研究。
IF 1.2 4区 医学 Q3 SURGERY Pub Date : 2025-05-01 Epub Date: 2025-04-28 DOI: 10.4174/astr.2025.108.5.271
Jiyoung Shin, Hye Young Woo, Eun-Ah Jo, Ara Cho, Ahram Han, Sanghyun Ahn, Sangil Min, Jongwon Ha

Purpose: Pancreas transplantation (PT) is a definitive treatment for diabetes mellitus (DM), restoring endogenous insulin secretion and improving glycemic control. Despite its efficacy, PT is less common in South Korea compared to Western nations. This study aims to report the clinical outcomes of PT over 2 decades at a single center, focusing on surgical techniques, complications, and graft survival.

Methods: A retrospective analysis of 69 PT recipients at Seoul National University Hospital between January 2002 and December 2023 was conducted. Data on recipient and donor demographics, surgical details, immunosuppressive regimens, and graft outcomes were collected. Graft survival was evaluated using Kaplan-Meier analysis, with subgroup comparisons using the log-rank test. Graft failure was defined as graft removal, PT re-registration, insulin dependence exceeding 0.5 units/kg/day for more than 90 days, or patient death.

Results: Among the 69 recipients, 50 (72.5%) had type 1 DM, and 18 (26.1%) had type 2 DM. Simultaneous pancreas-kidney (SPK) transplantations comprised 84.1% (n = 58), and pancreas-after-kidney (PAK) transplantations accounted for 10.1%. The 1-year and 5-year death-censored pancreas graft survival rates were 92.7% and 89.6%, respectively, with no significant difference between SPK and PAK (P = 0.330). Graft failure occurred in 10 patients, primarily due to pancreatitis and rejection. Donor-related factors, particularly anoxic brain injury, were significantly associated with lower graft survival (P = 0.045).

Conclusion: PT outcomes in this cohort align with international standards, emphasizing the importance of donor selection and tailored immunosuppression. Expanding PT indications to include selective type 2 DM patients could benefit South Korea's PT programs with adequate resource allocation.

目的:胰腺移植(PT)是治疗糖尿病(DM)的决定性手段,可恢复内源性胰岛素分泌,改善血糖控制。尽管它很有效,但与西方国家相比,PT在韩国并不常见。本研究的目的是在一个单一的中心报告PT超过20年的临床结果,重点是手术技术,并发症和移植物存活。方法:回顾性分析2002年1月至2023年12月在首尔国立大学医院接受PT治疗的69例患者。收集了受体和供体的人口统计数据、手术细节、免疫抑制方案和移植结果。采用Kaplan-Meier分析评估移植物存活,采用log-rank检验进行亚组比较。移植失败定义为移植物移除、PT重新登记、胰岛素依赖超过0.5单位/kg/天超过90天或患者死亡。结果:69例患者中,1型糖尿病患者50例(72.5%),2型糖尿病患者18例(26.1%)。同期胰肾(SPK)移植占84.1% (n = 58),胰肾后(PAK)移植占10.1%。1年和5年死亡切除胰腺移植存活率分别为92.7%和89.6%,SPK组与PAK组无显著差异(P = 0.330)。10例患者发生移植失败,主要原因是胰腺炎和排斥反应。供体相关因素,特别是缺氧脑损伤,与移植物存活率降低显著相关(P = 0.045)。结论:该队列的PT结果符合国际标准,强调了供体选择和量身定制的免疫抑制的重要性。扩大PT适应症以包括选择性2型糖尿病患者可以使韩国的PT项目受益,并有足够的资源分配。
{"title":"Outcomes of pancreas transplantation over two decades: a single-center retrospective cohort study.","authors":"Jiyoung Shin, Hye Young Woo, Eun-Ah Jo, Ara Cho, Ahram Han, Sanghyun Ahn, Sangil Min, Jongwon Ha","doi":"10.4174/astr.2025.108.5.271","DOIUrl":"https://doi.org/10.4174/astr.2025.108.5.271","url":null,"abstract":"<p><strong>Purpose: </strong>Pancreas transplantation (PT) is a definitive treatment for diabetes mellitus (DM), restoring endogenous insulin secretion and improving glycemic control. Despite its efficacy, PT is less common in South Korea compared to Western nations. This study aims to report the clinical outcomes of PT over 2 decades at a single center, focusing on surgical techniques, complications, and graft survival.</p><p><strong>Methods: </strong>A retrospective analysis of 69 PT recipients at Seoul National University Hospital between January 2002 and December 2023 was conducted. Data on recipient and donor demographics, surgical details, immunosuppressive regimens, and graft outcomes were collected. Graft survival was evaluated using Kaplan-Meier analysis, with subgroup comparisons using the log-rank test. Graft failure was defined as graft removal, PT re-registration, insulin dependence exceeding 0.5 units/kg/day for more than 90 days, or patient death.</p><p><strong>Results: </strong>Among the 69 recipients, 50 (72.5%) had type 1 DM, and 18 (26.1%) had type 2 DM. Simultaneous pancreas-kidney (SPK) transplantations comprised 84.1% (n = 58), and pancreas-after-kidney (PAK) transplantations accounted for 10.1%. The 1-year and 5-year death-censored pancreas graft survival rates were 92.7% and 89.6%, respectively, with no significant difference between SPK and PAK (P = 0.330). Graft failure occurred in 10 patients, primarily due to pancreatitis and rejection. Donor-related factors, particularly anoxic brain injury, were significantly associated with lower graft survival (P = 0.045).</p><p><strong>Conclusion: </strong>PT outcomes in this cohort align with international standards, emphasizing the importance of donor selection and tailored immunosuppression. Expanding PT indications to include selective type 2 DM patients could benefit South Korea's PT programs with adequate resource allocation.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"108 5","pages":"271-278"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re-do laparoscopic common bile duct exploration for recurrent common bile duct stones: a single-center retrospective cohort study. 再次腹腔镜胆总管探查复发性胆总管结石:一项单中心回顾性队列研究。
IF 1.2 4区 医学 Q3 SURGERY Pub Date : 2025-05-01 Epub Date: 2025-04-28 DOI: 10.4174/astr.2025.108.5.310
In Ho Lee, Seung Jae Lee, Ju Ik Moon, Sang Eok Lee, Nak Song Sung, Seong Uk Kwon, In Eui Bae, Seung Jae Rho, Sung Gon Kim, Min Kyu Kim, Dae Sung Yoon, Won Jun Choi, In Seok Choi

Purpose: Common bile duct (CBD) stone recurrence after laparoscopic CBD exploration (LCBDE) is relatively common. No studies have been conducted evaluating the safety and feasibility of re-do LCBDE in the treatment of recurrent CBD stones.

Methods: This single-center retrospective study reviewed 340 consecutive patients who underwent LCBDE for CBD stones between January 2004 and December 2020. Patients with pancreatobiliary malignancies and those who underwent other surgical procedures were excluded.

Results: Of the 340 included patients, 45 experienced a recurrence after a mean follow-up period of 24.2 months. Of them, 18 underwent re-do LCBDE, 20 underwent endoscopic intervention, 2 underwent radiologic intervention, and 5 underwent observation. Re-do LCBDE and initial LCBDE showed similar surgical outcomes in terms of operative time (113.1 minutes vs. 107.5 minutes, P = 0.515), estimated blood loss (42.5 mL vs. 49.1 mL, P = 0.661), open conversion rate (2.9% vs. 0%, P = 0.461), postoperative complication (15.3% vs. 22.2%, P = 0.430), and postoperative hospital stay (6.5 days vs. 6.4 days, P = 0.921). Comparing re-do LCBDE and nonsurgical treatment (endoscopic or radiologic), no statistically significant differences were noted in posttreatment complication (22.2% vs. 13.6%, P = 0.477), hospital stay (6.4 days vs.7.3 days, P = 0.607), and recurrence (50.0% vs. 36.4%, P = 0.385). The clearance rate was higher in the re-do LCBDE group than in the nonsurgical group (100% vs. 81.8%, P = 0.057).

Conclusion: Compared to initial LCBDE and endoscopic or radiological treatments, re-do LCBDE for recurrent CBD stones is a treatment option worth considering in selected patients.

目的:腹腔镜胆总管探查(LCBDE)后胆总管结石复发较为常见。目前还没有研究评估再做LCBDE治疗复发性CBD结石的安全性和可行性。方法:这项单中心回顾性研究回顾了2004年1月至2020年12月期间连续340例接受LCBDE治疗CBD结石的患者。胰胆管恶性肿瘤患者和接受过其他外科手术的患者被排除在外。结果:在340例纳入的患者中,45例在平均随访24.2个月后复发。其中重新行LCBDE 18例,内镜干预20例,放射干预2例,观察5例。在手术时间(113.1分钟对107.5分钟,P = 0.515)、估计失血量(42.5 mL对49.1 mL, P = 0.661)、开腹转换率(2.9%对0%,P = 0.461)、术后并发症(15.3%对22.2%,P = 0.430)和术后住院时间(6.5天对6.4天,P = 0.921)方面,Re-do LCBDE和初始LCBDE的手术结果相似。再行LCBDE与非手术治疗(内镜或放疗)比较,治疗后并发症(22.2%比13.6%,P = 0.477)、住院时间(6.4天比7.3天,P = 0.607)、复发率(50.0%比36.4%,P = 0.385)差异无统计学意义。再行LCBDE组清除率高于非手术组(100% vs. 81.8%, P = 0.057)。结论:与初始LCBDE和内镜或放射治疗相比,复发性CBD结石的再行LCBDE治疗是一种值得选择的治疗方案。
{"title":"Re-do laparoscopic common bile duct exploration for recurrent common bile duct stones: a single-center retrospective cohort study.","authors":"In Ho Lee, Seung Jae Lee, Ju Ik Moon, Sang Eok Lee, Nak Song Sung, Seong Uk Kwon, In Eui Bae, Seung Jae Rho, Sung Gon Kim, Min Kyu Kim, Dae Sung Yoon, Won Jun Choi, In Seok Choi","doi":"10.4174/astr.2025.108.5.310","DOIUrl":"https://doi.org/10.4174/astr.2025.108.5.310","url":null,"abstract":"<p><strong>Purpose: </strong>Common bile duct (CBD) stone recurrence after laparoscopic CBD exploration (LCBDE) is relatively common. No studies have been conducted evaluating the safety and feasibility of re-do LCBDE in the treatment of recurrent CBD stones.</p><p><strong>Methods: </strong>This single-center retrospective study reviewed 340 consecutive patients who underwent LCBDE for CBD stones between January 2004 and December 2020. Patients with pancreatobiliary malignancies and those who underwent other surgical procedures were excluded.</p><p><strong>Results: </strong>Of the 340 included patients, 45 experienced a recurrence after a mean follow-up period of 24.2 months. Of them, 18 underwent re-do LCBDE, 20 underwent endoscopic intervention, 2 underwent radiologic intervention, and 5 underwent observation. Re-do LCBDE and initial LCBDE showed similar surgical outcomes in terms of operative time (113.1 minutes <i>vs.</i> 107.5 minutes, P = 0.515), estimated blood loss (42.5 mL <i>vs.</i> 49.1 mL, P = 0.661), open conversion rate (2.9% <i>vs.</i> 0%, P = 0.461), postoperative complication (15.3% <i>vs.</i> 22.2%, P = 0.430), and postoperative hospital stay (6.5 days <i>vs.</i> 6.4 days, P = 0.921). Comparing re-do LCBDE and nonsurgical treatment (endoscopic or radiologic), no statistically significant differences were noted in posttreatment complication (22.2% <i>vs.</i> 13.6%, P = 0.477), hospital stay (6.4 days <i>vs.</i>7.3 days, P = 0.607), and recurrence (50.0% <i>vs.</i> 36.4%, P = 0.385). The clearance rate was higher in the re-do LCBDE group than in the nonsurgical group (100% <i>vs.</i> 81.8%, P = 0.057).</p><p><strong>Conclusion: </strong>Compared to initial LCBDE and endoscopic or radiological treatments, re-do LCBDE for recurrent CBD stones is a treatment option worth considering in selected patients.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"108 5","pages":"310-316"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumors arising from an axillary accessory breast: a 10-year retrospective cohort study at a single center. 腋窝副乳房肿瘤:单中心10年回顾性队列研究
IF 1.2 4区 医学 Q3 SURGERY Pub Date : 2025-05-01 Epub Date: 2025-04-28 DOI: 10.4174/astr.2025.108.5.302
Sung Ryul Lee, Ji Hyun Lee, Hyok Jo Kang

Purpose: Pathologic lesions may occur in an axillary accessory breast (AAB). This study aimed to evaluate the characteristics of tumors arising from AABs and to recommend appropriate treatment.

Methods: This retrospective study involved 3,544 women (18-65 years old) with AAB at Damsoyu Hospital in Korea from 2014 to 2023. The patients were divided into an AAB with benign tumors (TAAB) group and an AAB without tumors (AAB) group, and the tumors' pathologies were reviewed. A core biopsy was performed on tumors with possible malignancy identified by preoperative ultrasonography. All patients underwent complete excision of accessory mammary gland (AMG) tissue, including tumors. The postoperative results were checked 6 months after surgery.

Results: Fifty-two out of 3,554 patients had tumors confirmed by preoperative ultrasonography. Preoperative core biopsies were performed on 11 patients. Two patients had malignant tumors (invasive ductal carcinoma) identified by core biopsy. Fifty patients had benign tumors identified by postoperative pathological analysis (46 fibroadenomas, 2 fibrocystic changes, and 2 sclerosing adenoses). Carcinoma in situ was confirmed in 2 patients using postoperative pathological analysis. No patients in either group developed tumors in the axilla during the follow-up period. All patients were satisfied with the axillary pain relief and the disappearance of bulging lesions.

Conclusion: We recommend a core biopsy if preoperative ultrasonography indicates a possibly malignant tumor. AAB patients may experience tumors, pain, and bulging appearance of an AMG; thus, complete AMG excision is necessary.

目的:腋窝副乳(AAB)可能发生病理性病变。本研究旨在评估自身抗体引起的肿瘤的特点,并推荐适当的治疗方法。方法:本回顾性研究纳入2014年至2023年韩国Damsoyu医院3544例AAB女性(18-65岁)。将患者分为有良性肿瘤的AAB组(TAAB)和无肿瘤的AAB组(AAB),并回顾肿瘤的病理情况。术前超声检查发现可能为恶性的肿瘤,行核心活检。所有患者均行副乳腺(AMG)组织完全切除,包括肿瘤。术后6个月复查术后结果。结果:3554例患者术前超声检查确诊肿瘤52例。11例患者行术前核心活检。2例患者经核心活检证实为恶性肿瘤(浸润性导管癌)。术后病理分析发现良性肿瘤50例(纤维腺瘤46例,纤维囊性变2例,硬化性腺病2例)。术后病理分析证实2例为原位癌。在随访期间,两组患者均未出现腋窝肿瘤。所有患者均满意腋窝疼痛缓解和隆起性病变消失。结论:如果术前超声检查显示可能是恶性肿瘤,我们建议行核心活检。AAB患者可能会出现肿瘤、疼痛和AMG肿胀;因此,完全切除AMG是必要的。
{"title":"Tumors arising from an axillary accessory breast: a 10-year retrospective cohort study at a single center.","authors":"Sung Ryul Lee, Ji Hyun Lee, Hyok Jo Kang","doi":"10.4174/astr.2025.108.5.302","DOIUrl":"https://doi.org/10.4174/astr.2025.108.5.302","url":null,"abstract":"<p><strong>Purpose: </strong>Pathologic lesions may occur in an axillary accessory breast (AAB). This study aimed to evaluate the characteristics of tumors arising from AABs and to recommend appropriate treatment.</p><p><strong>Methods: </strong>This retrospective study involved 3,544 women (18-65 years old) with AAB at Damsoyu Hospital in Korea from 2014 to 2023. The patients were divided into an AAB with benign tumors (TAAB) group and an AAB without tumors (AAB) group, and the tumors' pathologies were reviewed. A core biopsy was performed on tumors with possible malignancy identified by preoperative ultrasonography. All patients underwent complete excision of accessory mammary gland (AMG) tissue, including tumors. The postoperative results were checked 6 months after surgery.</p><p><strong>Results: </strong>Fifty-two out of 3,554 patients had tumors confirmed by preoperative ultrasonography. Preoperative core biopsies were performed on 11 patients. Two patients had malignant tumors (invasive ductal carcinoma) identified by core biopsy. Fifty patients had benign tumors identified by postoperative pathological analysis (46 fibroadenomas, 2 fibrocystic changes, and 2 sclerosing adenoses). Carcinoma <i>in situ</i> was confirmed in 2 patients using postoperative pathological analysis. No patients in either group developed tumors in the axilla during the follow-up period. All patients were satisfied with the axillary pain relief and the disappearance of bulging lesions.</p><p><strong>Conclusion: </strong>We recommend a core biopsy if preoperative ultrasonography indicates a possibly malignant tumor. AAB patients may experience tumors, pain, and bulging appearance of an AMG; thus, complete AMG excision is necessary.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"108 5","pages":"302-309"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast cancer implant reconstructive surgery and radiotherapy: a retrospective analysis of medical records. 乳腺癌假体重建手术和放疗:医疗记录的回顾性分析。
IF 1.2 4区 医学 Q3 SURGERY Pub Date : 2025-05-01 Epub Date: 2025-04-28 DOI: 10.4174/astr.2025.108.5.295
Ji Young Yun, Ki Jung Ahn, Hyunjung Kim, Hee Yeon Kim, Tae Hyun Kim, Kyung Do Byun, Ji Sun Park, Yunseon Choi

Purpose: This study aimed to analyze whether the occurrence of complications increases if radiotherapy (RT) is administered after breast reconstructive surgery using implants.

Methods: This retrospective study included 80 patients who underwent breast reconstruction using implants, of which 16 (20.0%) underwent RT. Most patients underwent conventional fractionated RT (n = 13), and hypofractionated RT was performed in 3 patients. Most patients (n = 51, 63.8%) underwent delayed reconstruction, which involved implant replacement after tissue expander insertion. Only 29 patients (36.3%) underwent immediate reconstruction simultaneously with breast cancer surgery.

Results: The median postoperative follow-up was 39.9 months (range, 8.7-120.3 months). Complications occurred in 18 (22.5%); infection/necrosis (n = 8), leakage/rupture (n = 8), and capsular contracture (n = 2). Infection/necrosis is common in patients undergoing RT. Complications occurred in 4 patients (25.0%) who received RT and 14 (21.9%) who did not receive RT, and complications did not significantly increase with RT (P = 0.511). There was no overall difference in complications between the immediate (4 of 29) and delayed (14 of 51) reconstruction groups (P = 0.129). Nine patients underwent reoperation because of complications; 3 (18.8%) received RT and 6 (9.4%) did not receive RT. The reoperation rate did not increase significantly with RT (P = 0.254). There were 3 cases of recurrence, and patients who received RT had no recurrence.

Conclusion: RT did not significantly increase the complication or reoperation rates if reconstructive surgery was performed using implants. Therefore, RT should be performed in patients at a high risk of recurrence.

目的:本研究旨在分析乳房种植体重建术后放疗是否会增加并发症的发生。方法:回顾性研究80例乳房假体重建患者,其中16例(20.0%)接受了RT。大多数患者(n = 13)接受了常规分位RT, 3例患者进行了低分位RT。大多数患者(n = 51, 63.8%)进行了延迟重建,包括在组织扩张器插入后更换种植体。只有29例患者(36.3%)在乳腺癌手术的同时进行了立即重建。结果:术后中位随访39.9个月(范围8.7 ~ 120.3个月)。发生并发症18例(22.5%);感染/坏死(n = 8),渗漏/破裂(n = 8),包膜挛缩(n = 2)。感染/坏死在接受放射治疗的患者中很常见。接受放射治疗的患者中有4例(25.0%)出现并发症,未接受放射治疗的患者中有14例(21.9%)出现并发症,且并发症随放射治疗无显著增加(P = 0.511)。即刻(29例中4例)和延迟(51例中14例)重建组的并发症总体上无差异(P = 0.129)。9例因并发症再次手术;接受RT治疗3例(18.8%),未接受RT治疗6例(9.4%),再手术率随RT治疗无显著升高(P = 0.254)。复发3例,接受RT治疗的患者无复发。结论:采用种植体进行重建手术后,放疗对术后并发症及再手术率无显著影响。因此,复发风险高的患者应进行放疗。
{"title":"Breast cancer implant reconstructive surgery and radiotherapy: a retrospective analysis of medical records.","authors":"Ji Young Yun, Ki Jung Ahn, Hyunjung Kim, Hee Yeon Kim, Tae Hyun Kim, Kyung Do Byun, Ji Sun Park, Yunseon Choi","doi":"10.4174/astr.2025.108.5.295","DOIUrl":"https://doi.org/10.4174/astr.2025.108.5.295","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to analyze whether the occurrence of complications increases if radiotherapy (RT) is administered after breast reconstructive surgery using implants.</p><p><strong>Methods: </strong>This retrospective study included 80 patients who underwent breast reconstruction using implants, of which 16 (20.0%) underwent RT. Most patients underwent conventional fractionated RT (n = 13), and hypofractionated RT was performed in 3 patients. Most patients (n = 51, 63.8%) underwent delayed reconstruction, which involved implant replacement after tissue expander insertion. Only 29 patients (36.3%) underwent immediate reconstruction simultaneously with breast cancer surgery.</p><p><strong>Results: </strong>The median postoperative follow-up was 39.9 months (range, 8.7-120.3 months). Complications occurred in 18 (22.5%); infection/necrosis (n = 8), leakage/rupture (n = 8), and capsular contracture (n = 2). Infection/necrosis is common in patients undergoing RT. Complications occurred in 4 patients (25.0%) who received RT and 14 (21.9%) who did not receive RT, and complications did not significantly increase with RT (P = 0.511). There was no overall difference in complications between the immediate (4 of 29) and delayed (14 of 51) reconstruction groups (P = 0.129). Nine patients underwent reoperation because of complications; 3 (18.8%) received RT and 6 (9.4%) did not receive RT. The reoperation rate did not increase significantly with RT (P = 0.254). There were 3 cases of recurrence, and patients who received RT had no recurrence.</p><p><strong>Conclusion: </strong>RT did not significantly increase the complication or reoperation rates if reconstructive surgery was performed using implants. Therefore, RT should be performed in patients at a high risk of recurrence.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"108 5","pages":"295-301"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishment of an orthotopic nude mouse model for recurrent pancreatic cancer after complete resection: an experimental animal study. 胰腺癌完全切除后复发的原位裸鼠模型的建立:实验动物研究。
IF 1.2 4区 医学 Q3 SURGERY Pub Date : 2025-05-01 Epub Date: 2025-04-28 DOI: 10.4174/astr.2025.108.5.317
Sung Eun Park, Tae Ho Hong

Purpose: This study created a nude mouse model to study pancreatic cancer recurrence. Circumstances leading to the highest recurrence rates after curative surgery were also analyzed.

Methods: A total of 135 nude mice were divided into 3 groups: sham, metastasis, and resection (45 mice in each group). In sham and resection groups, AsPc-1 cells suspended in a synthetic extracellular matrix were injected into the tail of the pancreas of each mouse. In the metastasis group, cells were injected into the spleen. After 3 weeks, the resection group underwent distal pancreatectomy and the metastasis group underwent diagnostic laparotomy to confirm metastasis. To assess disease recurrence, the resection group was monitored weekly using luminescence imaging. Diagnostic exploration was conducted 3 weeks after surgery. Recurrence rate was evaluated and histological examination was performed for the resection group.

Results: Among 45 mice, 43 developed cancerous masses in the tail of the pancreas without invading adjacent organs 3 weeks after the initial orthotopic injection. Of those 43 mice, one died due to intraoperative bleeding during complete surgical resection. Pancreatic cancer recurrence was observed in 37 of 42 mice (88.1%) at an average of 21.8 ± 2.2 days. Histological examination showed high nuclear pleomorphism and neoangiogenesis.

Conclusion: We developed an efficient model that could demonstrate recurrence after complete resection of pancreatic cancer. By confirming that recurrence occurs after surgery using this protocol, our model is expected to contribute to the development of various treatment strategies.

目的:建立胰腺癌复发裸鼠模型。并分析了导致治愈性手术后复发率最高的情况。方法:将135只裸鼠分为假手术组、转移组和切除组,每组45只。在假手术组和切除组,将悬浮在合成细胞外基质中的AsPc-1细胞注射到每只小鼠的胰腺尾部。在转移组,将细胞注射到脾脏。3周后,切除组行远端胰腺切除术,转移组行诊断性开腹手术确认转移。为了评估疾病复发,切除组每周使用发光成像监测。术后3周进行诊断探查。对切除组进行复发率评估和组织学检查。结果:45只小鼠中,43只在首次原位注射3周后在胰腺尾部发生癌性肿块,但未侵犯邻近器官。在这43只小鼠中,有一只在完全手术切除过程中因术中出血而死亡。42只小鼠中有37只(88.1%)出现胰腺癌复发,平均复发时间为21.8±2.2天。组织学检查显示高核多形性和新生血管生成。结论:我们建立了一种有效的胰腺癌完全切除后复发模型。通过使用该方案确认手术后复发,我们的模型有望为各种治疗策略的发展做出贡献。
{"title":"Establishment of an orthotopic nude mouse model for recurrent pancreatic cancer after complete resection: an experimental animal study.","authors":"Sung Eun Park, Tae Ho Hong","doi":"10.4174/astr.2025.108.5.317","DOIUrl":"https://doi.org/10.4174/astr.2025.108.5.317","url":null,"abstract":"<p><strong>Purpose: </strong>This study created a nude mouse model to study pancreatic cancer recurrence. Circumstances leading to the highest recurrence rates after curative surgery were also analyzed.</p><p><strong>Methods: </strong>A total of 135 nude mice were divided into 3 groups: sham, metastasis, and resection (45 mice in each group). In sham and resection groups, AsPc-1 cells suspended in a synthetic extracellular matrix were injected into the tail of the pancreas of each mouse. In the metastasis group, cells were injected into the spleen. After 3 weeks, the resection group underwent distal pancreatectomy and the metastasis group underwent diagnostic laparotomy to confirm metastasis. To assess disease recurrence, the resection group was monitored weekly using luminescence imaging. Diagnostic exploration was conducted 3 weeks after surgery. Recurrence rate was evaluated and histological examination was performed for the resection group.</p><p><strong>Results: </strong>Among 45 mice, 43 developed cancerous masses in the tail of the pancreas without invading adjacent organs 3 weeks after the initial orthotopic injection. Of those 43 mice, one died due to intraoperative bleeding during complete surgical resection. Pancreatic cancer recurrence was observed in 37 of 42 mice (88.1%) at an average of 21.8 ± 2.2 days. Histological examination showed high nuclear pleomorphism and neoangiogenesis.</p><p><strong>Conclusion: </strong>We developed an efficient model that could demonstrate recurrence after complete resection of pancreatic cancer. By confirming that recurrence occurs after surgery using this protocol, our model is expected to contribute to the development of various treatment strategies.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"108 5","pages":"317-324"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy of skin soft tissue expansion and recombinant human epidermal growth factor in the repair of second-degree scald scars: a prospective single-blind randomized controlled trial. 皮肤软组织扩张和重组人表皮生长因子在二度烫伤瘢痕修复中的疗效:一项前瞻性单盲随机对照试验。
IF 1.2 4区 医学 Q3 SURGERY Pub Date : 2025-05-01 Epub Date: 2025-04-28 DOI: 10.4174/astr.2025.108.5.325
Hui He, Miaomiao Xu, Wenlu Zhang, Jia Ye

Purpose: This research observed the efficacy and safety of soft tissue expansion combined with recombinant human epidermal growth factor (rhEGF) in repairing second-degree scald scars.

Methods: This study conducted a prospective, single-blind, randomized controlled trial. Eighty-four patients with deep second-degree scald scars were evenly divided into the control and observation groups. The control group was treated with soft tissue expansion, and the observation group was additionally treated with rhEGF. The skin expansion and wound healing times were compared. The changes in wound exudate and inflammation around the wound were observed after first-stage surgery. The hydroxyproline (OHP) and collagen I/III ratios were compared during the second stage of surgery. The complications and repair effects during treatment were evaluated.

Results: The observation group exhibited lower expansion time, immediate retraction rate, and wound healing time, higher skin expansion rate, higher wound exudate score and inflammation score, higher OHP, lower collagen I/III, lower complication rate, and higher total effective rate than the control group (all P < 0.05).

Conclusion: Skin soft tissue expansion combined with rhEGF is more effective in repairing second-degree scald scars, which can effectively increase skin expansion area and reduce wound infection and complications.

目的:观察软组织扩张联合重组人表皮生长因子(rhEGF)修复二度烫伤疤痕的疗效和安全性。方法:采用前瞻性、单盲、随机对照试验。84例深二度烫伤瘢痕患者平均分为对照组和观察组。对照组给予软组织扩张治疗,观察组在对照组基础上给予rhEGF治疗。比较皮肤扩张和伤口愈合时间。观察一期手术后创面渗出及周围炎症的变化。在手术第二阶段比较羟基脯氨酸(OHP)和胶原I/III比率。观察治疗过程中的并发症及修复效果。结果:观察组患者扩张时间、即刻缩回率、创面愈合时间均低于对照组,皮肤扩张率、创面渗出评分、炎症评分、OHP、I/III胶原、并发症发生率均低于对照组,总有效率高于对照组(P < 0.05)。结论:皮肤软组织扩张联合rhEGF修复二度烫伤瘢痕更为有效,可有效增加皮肤扩张面积,减少创面感染及并发症。
{"title":"The efficacy of skin soft tissue expansion and recombinant human epidermal growth factor in the repair of second-degree scald scars: a prospective single-blind randomized controlled trial.","authors":"Hui He, Miaomiao Xu, Wenlu Zhang, Jia Ye","doi":"10.4174/astr.2025.108.5.325","DOIUrl":"https://doi.org/10.4174/astr.2025.108.5.325","url":null,"abstract":"<p><strong>Purpose: </strong>This research observed the efficacy and safety of soft tissue expansion combined with recombinant human epidermal growth factor (rhEGF) in repairing second-degree scald scars.</p><p><strong>Methods: </strong>This study conducted a prospective, single-blind, randomized controlled trial. Eighty-four patients with deep second-degree scald scars were evenly divided into the control and observation groups. The control group was treated with soft tissue expansion, and the observation group was additionally treated with rhEGF. The skin expansion and wound healing times were compared. The changes in wound exudate and inflammation around the wound were observed after first-stage surgery. The hydroxyproline (OHP) and collagen I/III ratios were compared during the second stage of surgery. The complications and repair effects during treatment were evaluated.</p><p><strong>Results: </strong>The observation group exhibited lower expansion time, immediate retraction rate, and wound healing time, higher skin expansion rate, higher wound exudate score and inflammation score, higher OHP, lower collagen I/III, lower complication rate, and higher total effective rate than the control group (all P < 0.05).</p><p><strong>Conclusion: </strong>Skin soft tissue expansion combined with rhEGF is more effective in repairing second-degree scald scars, which can effectively increase skin expansion area and reduce wound infection and complications.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"108 5","pages":"325-330"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of initial treatments for resectable hepatocellular carcinoma within Milan criteria: an observational study based on a nationwide survey. 米兰标准内可切除肝细胞癌的初始治疗比较:一项基于全国调查的观察性研究。
IF 1.2 4区 医学 Q3 SURGERY Pub Date : 2025-05-01 Epub Date: 2025-04-28 DOI: 10.4174/astr.2025.108.5.279
Sang Jin Kim, Woo Kyoung Jeong, Hyung-Joon Han, Gyu-Seong Choi, Kyun-Hwan Kim, Jongman Kim

Purpose: Treatment options for hepatocellular carcinoma (HCC) vary according to known guidelines among liver resection (LR), liver transplantation (LT), radiofrequency ablation (RFA), and transarterial chemoembolization (TACE). This study aimed to compare the outcomes of initial treatment for patients with resectable HCC within Milan criteria (MC) via nationwide data.

Methods: Patients with resectable HCC (Child-Pugh class A; platelet count, ≥100,000/µL) within MC from the Korean Liver Cancer Association databank were analyzed, retrospectively. Outcomes according to initial treatment and subgroups according to tumor size and number were analyzed. Overall survival (OS) rates after initial treatment were compared.

Results: A total of 3,241 patients who underwent LR (n = 1,371), LT (n = 12), RFA (n = 679), or TACE (n = 1,179) were included. The 5-year OS rates differed significantly between the groups (P < 0.05), except for LT (LR, 84.9%; LT, 82.5%; RFA, 76.2%; and TACE, 59.9%). For patients with a single tumor of any size, the 5-year OS rates of the LR group were significantly higher than RFA and TACE groups. For patients with multiple tumors, the 5-year OS rates were 78.2%, 100%, 74.3%, and 53.0% for the LR, LT, RFA, and TACE groups, respectively, but without significant difference between LR and RFA (P = 0.86).

Conclusion: For resectable HCC within MC, the LR had the highest OS rate for a single tumor of any size. LR and RFA showed no significant differences in OS rate for multiple tumors. LR has a much more optimistic outlook for HCC within MC.

目的:肝细胞癌(HCC)的治疗选择根据肝切除术(LR)、肝移植(LT)、射频消融(RFA)和经动脉化疗栓塞(TACE)的已知指南而有所不同。本研究旨在通过全国数据比较米兰标准(MC)下可切除HCC患者的初始治疗结果。方法:可切除HCC患者(Child-Pugh A类;回顾性分析韩国肝癌协会数据库中MC内血小板计数≥100,000/µL的患者。根据初始治疗的结果和肿瘤大小、数量的亚组进行分析。比较初始治疗后的总生存率(OS)。结果:共有3241例患者接受了LR (n = 1371)、LT (n = 12)、RFA (n = 679)或TACE (n = 1179)。各组间5年OS率差异有统计学意义(P < 0.05),但LT (LR, 84.9%;LT, 82.5%;RFA, 76.2%;TACE为59.9%)。对于任何大小的单一肿瘤患者,LR组的5年OS率明显高于RFA组和TACE组。对于多发性肿瘤患者,LR组、LT组、RFA组和TACE组的5年OS分别为78.2%、100%、74.3%和53.0%,LR组与RFA组无显著性差异(P = 0.86)。结论:对于MC内可切除的HCC, LR对于任何大小的单个肿瘤具有最高的OS率。LR和RFA在多发性肿瘤的OS率上无显著差异。LR对MC内HCC的前景更为乐观。
{"title":"Comparison of initial treatments for resectable hepatocellular carcinoma within Milan criteria: an observational study based on a nationwide survey.","authors":"Sang Jin Kim, Woo Kyoung Jeong, Hyung-Joon Han, Gyu-Seong Choi, Kyun-Hwan Kim, Jongman Kim","doi":"10.4174/astr.2025.108.5.279","DOIUrl":"https://doi.org/10.4174/astr.2025.108.5.279","url":null,"abstract":"<p><strong>Purpose: </strong>Treatment options for hepatocellular carcinoma (HCC) vary according to known guidelines among liver resection (LR), liver transplantation (LT), radiofrequency ablation (RFA), and transarterial chemoembolization (TACE). This study aimed to compare the outcomes of initial treatment for patients with resectable HCC within Milan criteria (MC) via nationwide data.</p><p><strong>Methods: </strong>Patients with resectable HCC (Child-Pugh class A; platelet count, ≥100,000/µL) within MC from the Korean Liver Cancer Association databank were analyzed, retrospectively. Outcomes according to initial treatment and subgroups according to tumor size and number were analyzed. Overall survival (OS) rates after initial treatment were compared.</p><p><strong>Results: </strong>A total of 3,241 patients who underwent LR (n = 1,371), LT (n = 12), RFA (n = 679), or TACE (n = 1,179) were included. The 5-year OS rates differed significantly between the groups (P < 0.05), except for LT (LR, 84.9%; LT, 82.5%; RFA, 76.2%; and TACE, 59.9%). For patients with a single tumor of any size, the 5-year OS rates of the LR group were significantly higher than RFA and TACE groups. For patients with multiple tumors, the 5-year OS rates were 78.2%, 100%, 74.3%, and 53.0% for the LR, LT, RFA, and TACE groups, respectively, but without significant difference between LR and RFA (P = 0.86).</p><p><strong>Conclusion: </strong>For resectable HCC within MC, the LR had the highest OS rate for a single tumor of any size. LR and RFA showed no significant differences in OS rate for multiple tumors. LR has a much more optimistic outlook for HCC within MC.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"108 5","pages":"279-294"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CORRIGENDUM: Correction of the grant number. Proposal of age definition for early-onset gastric cancer based on the Korean Gastric Cancer Association nationwide survey data: a retrospective observational study. 勘误表:补助金编号的更正。基于韩国胃癌协会全国调查数据的早发性胃癌年龄定义:回顾性观察性研究
IF 1.2 4区 医学 Q3 SURGERY Pub Date : 2025-05-01 Epub Date: 2025-04-28 DOI: 10.4174/astr.2025.108.5.331
Seong-A Jeong, Ji Sung Lee, Ba Ool Seong, Seul-Gi Oh, Chang Seok Ko, Sa-Hong Min, Chung Sik Gong, Beom Su Kim, Moon-Won Yoo, Jeong Hwan Yook, In-Seob Lee

[This corrects the article on p. 245 in vol. 108, PMID: 40226172.].

[这更正了第108卷第245页的文章,PMID: 40226172.]。
{"title":"CORRIGENDUM: Correction of the grant number. Proposal of age definition for early-onset gastric cancer based on the Korean Gastric Cancer Association nationwide survey data: a retrospective observational study.","authors":"Seong-A Jeong, Ji Sung Lee, Ba Ool Seong, Seul-Gi Oh, Chang Seok Ko, Sa-Hong Min, Chung Sik Gong, Beom Su Kim, Moon-Won Yoo, Jeong Hwan Yook, In-Seob Lee","doi":"10.4174/astr.2025.108.5.331","DOIUrl":"https://doi.org/10.4174/astr.2025.108.5.331","url":null,"abstract":"<p><p>[This corrects the article on p. 245 in vol. 108, PMID: 40226172.].</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"108 5","pages":"331-355"},"PeriodicalIF":1.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of portal/superior mesenteric vein abutment angle on prognosis in pancreatic cancer: a single-center retrospective cohort study. 门静脉/肠系膜上静脉基台角度对胰腺癌预后的影响:一项单中心回顾性队列研究
IF 1.2 4区 医学 Q3 SURGERY Pub Date : 2025-04-01 Epub Date: 2025-03-31 DOI: 10.4174/astr.2025.108.4.231
Hye Jeong Jeong, DanHui Heo, Soo Yeun Lim, Hyeong Seok Kim, Hochang Chae, So Jeong Yoon, Sang Hyun Shin, In Woong Han, Jin Seok Heo, Ji Hye Min, Hongbeom Kim

Purpose: Pancreatic cancer has a poor prognosis; however, the implementation of neoadjuvant treatment enables borderline resectable cases to undergo curative resection and improves the overall survival rate. Attempts have been made to expand the eligibility criteria for neoadjuvant treatment, even in resectable cases. Some studies have suggested a correlation between vein abutment and poor prognosis or that the abutment angle may affect prognosis. This study investigated the anatomical factors affecting the vessel abutment angle and its prognostic value in pancreatic cancer.

Methods: Patients with pancreatic ductal adenocarcinoma who underwent surgery between 2012 and 2017 were included in this study. Patients who underwent neoadjuvant treatment were excluded. Data from only the intent-to-treat pancreaticoduodenectomy group were included in the analysis. Clinicopathological characteristics; preoperative factors such as CA 19-9, preoperative biliary drainage, American Society of Anesthesiologists physical status classification, portal vein/superior mesenteric vein contact angle measured via CT scan; and intraoperative factors were collected for analysis.

Results: A total of 365 patients were included in this study, and the abutment group included 92 patients (25.2%). The abutment and no-contact groups did not show any significant differences in terms of the overall survival or disease-free survival rate. Among the abutment groups, patients with less than 90° and 90°-180° did not show any significant differences. In the multivariate analysis, the only preoperative factor that had a prognostic effect was CA 19-9, a biological factor.

Conclusion: When there is no vessel invasion in the abutment group, upfront surgery should be considered because the angle does not affect the overall prognosis.

目的:胰腺癌预后较差;然而,新辅助治疗的实施使边缘可切除的病例能够进行根治性切除并提高总生存率。已经尝试扩大新辅助治疗的资格标准,甚至在可切除的病例中。一些研究认为静脉基牙与预后不良有关,或者基牙角度可能影响预后。本研究探讨影响胰腺癌血管基台角度的解剖学因素及其预后价值。方法:本研究纳入2012年至2017年期间接受手术治疗的胰腺导管腺癌患者。接受新辅助治疗的患者排除在外。只有意向治疗胰十二指肠切除术组的数据被纳入分析。临床病理的特点;术前因素如CA 19-9、术前胆道引流、美国麻醉学会身体状态分类、门静脉/肠系膜上静脉CT扫描接触角;并收集术中因素进行分析。结果:本研究共纳入365例患者,其中基牙组92例(25.2%)。基台组和非接触组在总生存率和无病生存率方面没有显着差异。在基台组中,小于90°和90°-180°患者无显著性差异。在多因素分析中,唯一影响预后的术前因素是CA 19-9,这是一个生物学因素。结论:当基台组无血管侵犯时,由于角度不影响整体预后,可考虑进行前期手术。
{"title":"Impact of portal/superior mesenteric vein abutment angle on prognosis in pancreatic cancer: a single-center retrospective cohort study.","authors":"Hye Jeong Jeong, DanHui Heo, Soo Yeun Lim, Hyeong Seok Kim, Hochang Chae, So Jeong Yoon, Sang Hyun Shin, In Woong Han, Jin Seok Heo, Ji Hye Min, Hongbeom Kim","doi":"10.4174/astr.2025.108.4.231","DOIUrl":"https://doi.org/10.4174/astr.2025.108.4.231","url":null,"abstract":"<p><strong>Purpose: </strong>Pancreatic cancer has a poor prognosis; however, the implementation of neoadjuvant treatment enables borderline resectable cases to undergo curative resection and improves the overall survival rate. Attempts have been made to expand the eligibility criteria for neoadjuvant treatment, even in resectable cases. Some studies have suggested a correlation between vein abutment and poor prognosis or that the abutment angle may affect prognosis. This study investigated the anatomical factors affecting the vessel abutment angle and its prognostic value in pancreatic cancer.</p><p><strong>Methods: </strong>Patients with pancreatic ductal adenocarcinoma who underwent surgery between 2012 and 2017 were included in this study. Patients who underwent neoadjuvant treatment were excluded. Data from only the intent-to-treat pancreaticoduodenectomy group were included in the analysis. Clinicopathological characteristics; preoperative factors such as CA 19-9, preoperative biliary drainage, American Society of Anesthesiologists physical status classification, portal vein/superior mesenteric vein contact angle measured via CT scan; and intraoperative factors were collected for analysis.</p><p><strong>Results: </strong>A total of 365 patients were included in this study, and the abutment group included 92 patients (25.2%). The abutment and no-contact groups did not show any significant differences in terms of the overall survival or disease-free survival rate. Among the abutment groups, patients with less than 90° and 90°-180° did not show any significant differences. In the multivariate analysis, the only preoperative factor that had a prognostic effect was CA 19-9, a biological factor.</p><p><strong>Conclusion: </strong>When there is no vessel invasion in the abutment group, upfront surgery should be considered because the angle does not affect the overall prognosis.</p>","PeriodicalId":8071,"journal":{"name":"Annals of Surgical Treatment and Research","volume":"108 4","pages":"231-239"},"PeriodicalIF":1.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of Surgical Treatment and Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1